Evidence map›Paper›PMID 33034147›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2021

MicroRNA-34a-5p Promotes Joint Destruction During Osteoarthritis.

Helal Endisha, Poulami Datta, Anirudh Sharma, Sayaka Nakamura, Evgeny Rossomacha, Carolen Younan, Shabana A Ali, Ghazaleh Tavallaee, Starlee Lively, Pratibha Potla and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 1 synthesis or guideline pooled it, 130 citations in OpenAlex.

  1. MicroRNA expression in osteoarthritis: a meta-analysis.Clinical and experimental medicine · 2023
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Antisense Oligonucleotide Therapeutics Targeting Age-Related Diseases.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. [Aucubin alleviates knee osteoarthritis in mice by suppressing the NF‑κB signaling pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
    Article
  17. Article
  18. Review
  19. Article
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 2 countries.

Helal EndishaKrembil Research Institute, University Health Network, and, University of Toronto, Toronto, Ontario, Canada.
Poulami DattaKrembil Research Institute, University Health Network, Toronto, Ontario, Canada.
Anirudh SharmaKrembil Research Institute, University Health Network, Toronto, Ontario, Canada.
Sayaka NakamuraKrembil Research Institute, University Health Network, Toronto, Ontario, Canada.
Evgeny RossomachaKrembil Research Institute, University Health Network, Toronto, Ontario, Canada.
Carolen YounanKrembil Research Institute, University Health Network, Toronto, Ontario, Canada.
Shabana A AliKrembil Research Institute, University Health Network, Toronto, Ontario, Canada.
Ghazaleh TavallaeeKrembil Research Institute, University Health Network, and, University of Toronto, Toronto, Ontario, Canada.
Starlee LivelyKrembil Research Institute, University Health Network, Toronto, Ontario, Canada.
Pratibha PotlaKrembil Research Institute, University Health Network, Toronto, Ontario, Canada.
Konstantin ShestopaloffKrembil Research Institute, University Health Network, Toronto, Ontario, Canada.
Jason S RockelKrembil Research Institute, University Health Network, Toronto, Ontario, Canada.
Roman KrawetzMcCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada.
Nizar N MahomedKrembil Research Institute, and Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.
Igor JurisicaIgor Jurisica,: Krembil Research Institute, University Health Network, University of Toronto, Toronto, Ontario, Canada, and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia.
Rajiv GandhiKrembil Research Institute, and Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.
Mohit KapoorKrembil Research Institute, University Health Network, and University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0001-9877-0772
University Health Network · CAUniversity of Calgary · CA

Funding

Canadian Institute of Health Research Operating grant
6 · The paper itself

Abstract

objectiveMicroRNA-34a-5p (miR-34a-5p) expression is elevated in the synovial fluid of patients with late-stage knee osteoarthritis (OA); however, its exact role and therapeutic potential in OA remain to be fully elucidated. This study was undertaken to examine the role of miR-34a-5p in OA pathogenesis.

methodsExpression of miR-34a-5p was determined in joint tissues and human plasma (n = 71). Experiments using miR-34a-5p mimic or antisense oligonucleotide (ASO) treatment were performed in human OA chondrocytes, fibroblast-like synoviocytes (FLS) (n = 7-9), and mouse OA models, including destabilization of the medial meniscus (DMM; n = 22) and the accelerated, more severe model of mice fed a high-fat diet and subjected to DMM (n = 11). Wild-type (WT) mice (n = 9) and miR-34a-knockout (KO) mice (n = 11) were subjected to DMM. Results were expressed as the mean ± SEM and analyzed by t-test or analysis of variance, with appropriate post hoc tests. P values less than 0.05 were considered significant. RNA sequencing was performed on WT and KO mouse chondrocytes.

resultsExpression of miR-34a-5p was significantly increased in the plasma, cartilage, and synovium of patients with late-stage OA and in the cartilage and synovium of mice subjected to DMM. Plasma miR-34a-5p expression was significantly increased in obese patients with late-stage OA, and in the plasma and knee joints of mice fed a high-fat diet. In human OA chondrocytes and FLS, miR-34a-5p mimic increased key OA pathology markers, while miR-34a-5p ASO improved cellular gene expression. Intraarticular miR-34a-5p mimic injection induced an OA-like phenotype. Conversely, miR-34a-5p ASO injection imparted cartilage-protective effects in the DMM and high-fat diet/DMM models. The miR-34a-KO mice exhibited protection against DMM-induced cartilage damage. RNA sequencing of WT and KO chondrocytes revealed a putative miR-34a-5p signaling network.

conclusionOur findings provide comprehensive evidence of the role and therapeutic potential of miR-34a-5p in OA.

Indexed as

AdultAgedAnimalsCartilage, ArticularChondrocytesDiet, High-FatDisease Models, AnimalFemaleHumansMaleMenisci, TibialMiceMice, KnockoutMicroRNAsMiddle AgedOligonucleotides, AntisenseMicroRNAsMIRN34a microRNA, mouseMIRN34 microRNA, humanOligonucleotides, Antisense

Identifiers

PMID33034147
PMCPMC7986901
OpenAlexW3092209489

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.